जागतिक पातळीवर सुधारित पेशी आणि जीन उपचार पद्धतीच्या मानचित्रात भारतास स्थान मिळवून देणारे भारतात प्रथम बनविलेले मानवीय सी.ए.आर. टी पेशी उपचार हे ___ लक्ष्यित उत्पादन आहे.

The correct answer is Option C (CD 19).

Key Points:
• CAR-T Cell Therapy: Chimeric Antigen Receptor (CAR) T-cell therapy is a revolutionary, advanced form of cancer immunotherapy. It involves extracting a patient's T-cells, genetically engineering them in a lab to produce receptors (CARs) that target specific cancer cells, and infusing them back into the patient.
• 🇮🇳 India's First Indigenous CAR-T Therapy: In late 2023, India achieved a massive milestone when the national drug regulator approved NexCAR19 (Actalycabtagene autoleucel). This therapy was developed collaboratively by IIT Bombay and Tata Memorial Centre, and incubated by the startup ImmunoACT. It brings the cost of this therapy down from crores of rupees to a fraction of the price.
• The Specific Target: NexCAR19 is specifically designed to treat B-cell cancers (like B-cell lymphomas and acute lymphoblastic leukemia). It does this by aggressively targeting a specific protein/antigen found on the surface of these malignant B-cells. This target protein is CD19.
• Conclusion: Therefore, it is a CD19 targeted product.
• Key Takeaway: India's first indigenous CAR-T cell therapy (NexCAR19) specifically targets the CD19 protein found on malignant B-cells to cure blood cancers.